169 research outputs found
Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients
PURPOSE. We verified whether prostate adenocarcinoma produces specific modifications in DC subsets count. METHODS. Twenty-one untreated prostate adenocarcinomas were divided on the basis of clinical stage in localized and metastatic disease. As control we used a population of 18 healthy male subjects. For DCs enumeration, peripheral blood (PB) samples were obtained in all cases. A single-platform flow cytometric assay based on Tru-COUNT was used for the enumeration of the two DCs subsets, myeloid (mDCs) and plasmacytoid (pDCs). RESULTS. We showed a statistically significant reduction in pDCs count in prostate cancer population when compared to healthy controls (P = 0.002). Comparing each clinical stage with healthy controls, significant differences were found between controls and the metastatic group in both pDCs and mDCs (P = 0.005 and P = 0.023 respectively) but not between controls and the localized group (P = 0.055 and P = 0.829 respectively). CONCLUSIONS. We showed that DCs count in PB is significantly affected by prostate adenocarcinoma progression in a metastatic disease. © 2006 Wiley-Liss, Inc
Efficacy of antiseptic mouthrinses against SARS-CoV-2: A prospective randomized placebo-controlled pilot study
Coronavirus-disease-19 (COVID-19) continues to affect millions of individuals worldwide. Antiviral activity of mouthrinses remains an important research area as the oral cavity is a site of SARS-CoV-2 initial replication. The aim of this study was to assess the effectiveness of three different mouthrinses in reducing the oral/oropharyngeal SARS-CoV-2 viral load.Objectives: Coronavirus-disease-19 (COVID-19) continues to affect millions of individuals worldwide. Antiviral
activity of mouthrinses remains an important research area as the oral cavity is a site of SARS-CoV-2 initial
replication. The aim of this study was to assess the effectiveness of three different mouthrinses in reducing the
oral/oropharyngeal SARS-CoV-2 viral load.
Methods: Adult patients, hospitalized with confirmed COVID-19 were recruited for the study. Oral/oropharyngeal
baseline SARS-CoV-2 samples were collected and analyzed by Real-Time-PCR. Subsequently, patients were
instructed to rinse with 1 % hydrogen peroxide (H2O2), 0.12 % chlorhexidine (CHX), 1 % povidone‑iodine (PVPI)
or Sodium Chloride 0.9 % (placebo). Viral loads were measured right after (T1), and at 45 min (T2) from the
rinse.
Results: In the PVP-I 1 % group, 5/8 (62.5 %) patients at T1, and 3/8 (37.5 %) patients at T2, SARS-CoV-2 was not
detectable in the swab specimens. In the H2O2 1 % group, 2/11 (18.2 %) patients at T1, and 2/11 (18.2 %) other
patients at T2 showed no SARS-CoV-2 loads. One (12.5 %) patient in the CHX 0.12 % group showed SARS-CoV-2
negativity at T2. One (9.1 %) patient at T1, and another (9.1 %) patient at T2 showed no SARS-CoV-2 loads in the
placebo group.
Conclusions: Oral SARS-CoV-2 loads were reduced at T1 in the PVP-I 1 % and H2O2 1 % groups.
Clinical relevance: PVP-I 1 % was the most effective rinse especially in patients with low viral copy numbers at
baseline
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy
Whilst renal dysfunction, especially mild impairment (60<eGFR<90 ml/min), has been often described in HIV-infected population, its potential contribution to HIV evolution and risk of cerebro-cardiovascular disease (CCVD) has not been clarified. Data from HIV-1 infected patients enrolled in the Italian Cohort of Antiretroviral-Naïve (Icona) Foundation Study collected between January 2000 and February 2014 with at least two creatinine values available. eGFR (CKD-epi) and renal dysfunction defined using a priori cut-offs of 60 (severely impaired) and 90 ml/min/1.73m2 (mildly impaired). Characteristics of patients were described after stratification in these groups and compared using chi-square test (categorical variables) or Kruskal Wallis test comparing median values. Follow-up accrued from baseline up to the date of the CCVD or AIDS related events or death or last available visit. Kaplan Meier curves were used to estimate the cumulative probability of occurrence of the events over time. Adjusted analysis was performed using a proportional hazards Cox regression model. We included 7,385 patients, observed for a median follow-up of 43 months (inter-quartile range [IQR]: 21-93 months). Over this time, 130 cerebro-cardiovascular events (including 11 deaths due to CCVD) and 311 AIDS-related events (including 45 deaths) were observed. The rate of CCVD events among patients with eGFR >90, 60-89, <60 ml/min, was 2.91 (95% CI 2.30-3.67), 4.63 (95% CI 3.51-6.11) and 11.9 (95% CI 6.19-22.85) per 1,000 PYFU respectively, with an unadjusted hazard ratio (HR) of 4.14 (95%CI 2.07-8.29) for patients with eGFR <60 ml/min and 1.58 (95%CI 1.10-2.27) for eGFR 60-89 compared to those with eGFR ≥90. Of note, these estimates are adjusted for traditional cardio-vascular risk factors (e.g. smoking, diabetes, hypertension, dyslipidemia). Incidence of AIDS-related events was 9.51 (95%CI 8.35-10.83), 6.04 (95%CI 4.74-7.71) and 25.0 (95%CI 15.96-39.22) per 1,000 PYFU, among patients with eGFR >90, 60-89, <60 ml/min, respectively, with an unadjusted HR of 2.49 (95%CI 1.56-3.97) for patients with eGFR <60 ml/min and 0.68 (95%CI 0.52-0.90) for eGFR 60-89. The risk of AIDS events was significantly lower in mild renal dysfunction group even after adjustment for HIV-related characteristics. Our data confirm that impaired renal function is an important risk marker for CCVD events in the HIV-population; importantly, even those with mild renal impairment (90<eGFR<60) seem to be at increased risk of cerebro-cardiovascular morbidity and mortality
Comparison between hospitalized patients affected or not by COVID-19 (RESILIENCY study)
Dear Editor,
in the recent report of Munblit and coworkers [1], authors observed that the
combination of clinical features was sufficient to diagnose COVID-19 indicating that
laboratory testing is not critical in real-life clinical practice. To date, all patients admitted to
Emergency Department with acute respiratory failure and/or fever should be considered as a
suspected SARS-CoV-2 infection [2-3], and an early recognition of etiology and the prompt
therapeutic management are crucial to improve survival [4-5].
From March to July 2020, we performed a prospective, multicenter study
(RESILIENCY study). During the study period, all patients hospitalized for suspected or
confirmed COVID-19 were prospectively recruited in 3 large hospitals in Rome, Italy. All
patients with suspected SARS-CoV-2 infection, admitted to the hospital in case of fever
and/or hypoxemic respiratory failure (PaO2 <60 mmHg at rest in ambient air) or of
exacerbation of underlying diseases or severe symptoms not manageable outside the hospital,
were evaluated according to a predefined protocol (see Figure 1).
Overall, 653 patients were included in the study: 309 (47.3%) patients with confirmed
COVID-19 and 344 (52.7%) without COVID-19, hospitalized for other causes. Baseline
characteristics and outcomes of the study population showed that the main causes of
hospitalization among patients without COVID-19 were: acute heart failure (47%), bacterial
pneumonia (38.5%), and pulmonary embolism (9.2%). Overall, 67 (21.7%) patients of
COVID-19 group and 45 (13.1%) hospitalized for other causes were admitted to intensive
care unit; 30-day mortality was observed in 59 (19%) patients of COVID-19 group and 62
(18%) of non-COVID-19 group.
The multivariate analysis about risk factors for COVID-19 etiology at time of
hospitalization showed that dry cough (OR 3.76, CI 95% 1.98-7.92, P<0.001), duration of
fever>3 days (OR 5.21, CI 95% 2.34-9.21, P<0.001), lymphocytopenia (OR 1.98, CI 95%
Downloaded from https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1745/5989494 by Sapienza Università di Roma user on 01 December 2020
Accepted Manuscript
3
1.27-4.22, P=0.002) and PaO2/FiO2 ratio<250 (OR 4.98, CI 95% 2.22-9.71, P<0.001) were
independently associated with COVID-19 etiology, while procalcitonin value>1 ng/ mL (OR
0.21, CI 95% 0.08-0.82, p<0.001), and lactate>2 mmol/L (OR 0.41, CI 95% 0.15-0.77,
p<0.001) were associated with non-COVID-19 etiology.
Finally, analysis about predictors of 30-day mortality showed that age (per-year
increase OR 1.33; CI 95% 1.11-2.10; p<0.001), cardiovascular disease (OR 4.58; CI 95%
2.07-8.25; p<0.001), and ICU admission (OR 2.1; CI 95% 1.48-4.4; p<0.001) were
independently associated with all-cause 30-day mortality, while the use of low-molecularweight heparin (OR 0.22, CI 95% 0.03-0.45, p=0.002) was associated with survival.
The findings of the present study can be summarized as follows:1) the prompt
identification of specific clinical characteristics (like dry cough or duration of fever>3 days),
and laboratory findings (like lymphocytopenia, PaO2/FiO2 ratio<250, procalcitonin value>1
ng/ mL, and lactate>2 mmol/L) can help physicians to distinguish rapidly between COVID19 or other etiologies [6]; 2) the application of a standard approach to management of
patients with acute respiratory failure and/or fever associated with the knowledge of clinical
and laboratory characteristics of COVID-19 can early drive physicians to therapeutic choices;
and 3) age, cardiovascular disease, and ICU admission show an independent association with
all-cause 30-day mortality [7], while the use of low-molecular-weight heparin was associated
with survival [8].
In conclusion, COVID-19 syndrome is characterized by a heterogeneous clinical,
laboratoristic, and radiological presentation, especially at its onset [9]. However, the application of a
standard approach to management of patients with acute respiratory failure and/or fever and the
knowledge of clinical and laboratory characteristics of COVID-19 can early drive therapeutic choic
Xerostomia, gustatory and olfactory dysfunctions in patients with COVID-19
Background
The novel Coronavirus Disease-19 (COVID-19) continues to have profound effect on global health. Our aim was to evaluate the prevalence and characterize specific symptoms associated with COVID-19.
Methods
This retrospective study included 326 patients with confirmed SARS-CoV-2 infection evaluated at the Emergency Department of the Umberto I Polyclinic Hospital, Rome, Italy between March 6th and April 30th, 2020. In order to assess xerostomia, olfactory and gustatory dysfunctions secondary to COVID-19, a telephone-based a modified survey obtained from the National Health and Nutrition Examination Survey (NHANES) 2013–2014 for taste and smell disorders and the Fox Questionnaire for dry mouth were administered to 111 patients (34%) after discharge between June 4th and June 12th.
Results
Taste dysfunction was the most common reported symptom (59.5%; n = 66), followed by xerostomia (45.9%; n = 51) and olfactory dysfunctions (41.4%; n = 46). The most severe symptom was olfactory dysfunction with a median severity score of 8.5 (range: 5–10). Overall 74.5% (n = 38) of patients with xerostomia, 78.8% (n = 52) of patients with gustatory dysfunctions and 71.1% (n = 33) of patients with olfactory dysfunctions reported that all symptoms appeared before COVID-19 diagnosis. Overall, the majority of patients reported one symptom only (45.9%, n = 51), 37 (33.3%) reported the association of two symptoms, and 23 (20.7%) patients reported the association of three symptoms at the same time.
Conclusion
Xerostomia, gustatory and olfactory dysfunctions may present as a prodromal or as the sole manifestation of COVID-19. Awareness is fundamental to identify COVID-19 patients at an early stage of the disease and limit the spread of the virus
Targeting microbiome: an alternative strategy for fighting SARS-CoV-2 infection
Respiratory and gastrointestinal symptoms are the predominant clinical manifestations of the coronavirus disease 2019 (COVID-19). Infecting intestinal epithelial cells, the severe acute respiratory syndrome coronavirus-2 may impact on host's microbiota and gut inflammation. It is well established that an imbalanced intestinal microbiome can affect pulmonary function, modulating the host immune response ("gut-lung axis"). While effective vaccines and targeted drugs are being tested, alternative pathophysiology-based options to prevent and treat COVID-19 infection must be considered on top of the limited evidence-based therapy currently available. Addressing intestinal dysbiosis with a probiotic supplement may, therefore, be a sensible option to be evaluated, in addition to current best available medical treatments. Herein, we summed up pathophysiologic assumptions and current evidence regarding bacteriotherapy administration in preventing and treating COVID-19 pneumonia
Oral Bacteriotherapy Reduces the Occurrence of Chronic Fatigue in COVID-19 Patients
Long COVID refers to patients with symptoms as fatigue, “brain fog,” pain, suggesting the chronic involvement of the central nervous system (CNS) in COVID-19. The supplementation with probiotic (OB) would have a positive effect on metabolic homeostasis, negatively impacting the occurrence of symptoms related to the CNS after hospital discharge. On a total of 58 patients hospitalized for COVID-19, 24 (41.4%) received OB during hospitalization (OB+) while 34 (58.6%) taken only the standard treatment (OB–). Serum metabolomic profiling of patients has been performed at both hospital acceptance (T0) and discharge (T1). Six months after discharge, fatigue perceived by participants was assessed by administrating the Fatigue Assessment Scale. 70.7%of participants reported fatigue while 29.3%were negative for such condition. The OB+ group showed a significantly lower proportion of subjects reporting fatigue than the OB– one (p < 0.01). Furthermore, OB+ subjects were characterized by significantly increased concentrations of serum Arginine, Asparagine, Lactate opposite to lower levels of 3-Hydroxyisobutirate than those not treated with probiotics. Our results strongly suggest that in COVID-19, the administration of probiotics during hospitalization may prevent the development of chronic fatigue by impacting key metabolites involved in the utilization of glucose as well as in energy pathways
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial
Objectives
Primary study outcome was absence of treatment failure (virological failure, VF, or treatment interruption) per protocol at week 48.
Methods
Patients on 3-drug ART with stable HIV-1 RNA <50 copies/mL and CCR5-tropic virus were
randomized 1:1 to maraviroc with darunavir/ritonavir qd (study arm) or continue current ART
(continuation arm).Results
In June 2015, 115 patients were evaluable for the primary outcome (56 study, 59 continuation arm). The study was discontinued due to excess of VF in the study arm (7 cases,
12.5%, vs 0 in the continuation arm, p = 0.005). The proportion free of treatment failure was
73.2% in the study and 59.3% in the continuation arm. Two participants in the study and 10
in the continuation arm discontinued therapy due to adverse events (p = 0.030). At VF, no
emergent drug resistance was detected. Co-receptor tropism switched to non-R5 in one
patient. Patients with VF reported lower adherence and had lower plasma drug levels. Femoral bone mineral density was significantly improved in the study arm.
Conclusion
Switching to maraviroc with darunavir/ritonavir qd in virologically suppressed patients was
associated with improved tolerability but was virologically inferior to 3-drug therap
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort
Background Real-life data on access and response to direct antiviral agents (DAA) in HIV-HCV coinfected individuals are lacking. Methods HCV viremic, HIV-positive patients from Icona and Hepaicona cohorts nave to DAA by January 2013 were included. Access and predictors of starting DAA were evaluated. Switches of antiretroviral drugs at starting DAA were described. We calculated sustained virological response (SVR12) in those reaching 12 weeks after end-of-treatment (EOT), and defined treatment failure (TF) as discontinuation of DAA before EOT or non-SVR12. Statistical analyses included Kaplan-Meier curves, univariable and multivariable analyses evaluating predictors of access to DAA and of treatment outcome (non-SVR and TF). Results 2,607 patients included. During a median follow-up of 38 (IQR:30-41) months, 920 (35.3%) patients started DAA. Eligibility for reimbursement was the strongest predictor to access to treatment: 761/1,090 (69.8%) eligible and 159/1,517 (10.5%) non-eligible to DAA reimbursement. Older age, HIV-RNA50 copies/mL were associated to faster DAA initiation, higher CD4 count and HCV-genotype 3 with delayed DAA initiation in those eligible to DAA reimbursement. Up to 28% of patients (36% of those on ritonavir-boosted protease inhibitors, PI/r) underwent antiretroviral (ART) modification at DAA initiation. 545/595 (91.6%) patients reaching EOT achieved SVR12. Overall, TF occurred in 61/606 patients (10.1%), with 11 discontinuing DAA before EOT. Suboptimal DAA was the only independent predictor of both non-SVR12 (AHR 2.52, 95%CI:1.24-5.12) and TF (AHR: 2.19; 95%CI:1.13-4.22). Conclusions Only 35.3% had access to HCV treatment. Despite excellent rates of SVR12 rates (91.6%), only 21% (545/2,607) of our HIV-HCV co-infected patients are cured. © 2017 d'Arminio Monforte et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Upper mantle control on the W isotope record of shallow level plume and intraplate volcanic settings
Several studies have revealed small heterogeneities in the relative abundance of 182W, the radiogenic nuclide of short-lived 182Hf (t1/2 = ∼9 Ma), in terrestrial rocks. Whereas the majority of Archean rocks display 182W excesses relative to bulk silicate Earth, many young ocean island basalts show small 182W deficits, in particular if they are sourced from deep-rooted mantle plumes. The origin of this anomaly is still ambiguous, proposed models focus on core-mantle interaction or the presence of reservoirs in the lower mantle that have been isolated since the Hadean. In order to evaluate the role of upper mantle reservoirs, we report the first 182W data for intraplate basalts where a deep plume origin is still debated (Ascension Island, Massif Central, Siebengebirge and Eifel) and intraplate volcanic rocks associated with either plume or subduction zone environments (Italian Magmatic Provinces) and compare them to new data for basalts that have a deep mantle plume origin (La Réunion and Baffin Island). The proto-Iceland plume basalts from Baffin Island have uniform and modern mantle-like W of around 0 despite extremely high (3He/4He). In contrast, basalts from both volcanic edifices from La Réunion span a range from modern upper mantle values to deficits as low as W = −8.8 ppm, indicating a heterogeneous source reservoir. The W in all other intraplate volcanic provinces overlap the composition of modern upper mantle to within 3 ppm. The absence of resolvable 182W anomalies in these intraplate basalts, which partially tap the lithospheric mantle, suggests that primordial components are neither present in the central and southern European lithosphere nor in the European asthenospheric reservoir (EAR). The general absence of 182W anomalies in European plume-related basalts can either be explained by a shallow mantle source or by the absence of isotopically anomalous and isolated domains in the deep mantle beneath the northern hemisphere, as also suggested by geophysical evidence
- …